Cancer treatment with c-met antagonists and correlation of the latter with HGF expression
AssigneeGenentech, Inc.
InventorsWei Yu, David Shames, Hartmut Koeppen, See Phan, Sandra Rost
Life of this patent
Estimating the term…
Abstract
The present invention concerns cancer biomarkers. In particular, the invention concerns HGF as a biomarker for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
Claims25
A method for treating a patient with cancer comprising administering an effective amount of a c-met antagonist to the patient if the patient's cancer is known to have a high amount of the HGF biomarker, wherein the patient's cancer is previously treated glioblastoma, wherein HGF biomarker is HGF mRNA, and HGF biomarker mRNA expression is assayable in a sample from the patient using in situ hybridization (ISH), wherein high HGF biomarker is:
- (a) an ISH score of 2+ and/or 3+;
- (b) presence of about 12 or more HGF ISH signal positive cells in the sample;
- or
- (c) 1% or more HGF ISH signal positive cells in the sample.
Dependencies are inferred from the claim text.